The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Srdan Verstovsek, MD, PhD, discusses the different phases of myeloproliferative neoplasms.

Lucia Masarova, MD, discusses the toxicities associated with the combination of JAK inhibitors and other targeted therapies in patients with myelofibrosis.

Isabella C. Glitza Oliva, MD, PhD, MS, discusses ​the potential utility of pembrolizumab in combination with selinexor in advanced melanoma.

In our exclusive interview, Dr. Tripathy discusses the state of treatment in metastatic HER2-positive breast cancer, current sequencing strategies, and targeted agents under evaluation in this setting.

Prithviraj Bose, MD, discusses novel agents under investigation in essential thrombocythemia.

Naveen Pemmaraju, MD, discusses the need to develop novel therapies in myeloproliferative neoplasms.

Shannon N. Westin, MD, MPH, discusses remaining challenges in endometrial cancer.

Van K. Morris, MD, discusses the design of the prospective phase 2/3 NRG-GI005 (COBRA) trial evaluating circulating tumor DNA as a predictive biomarker for adjuvant chemotherapy in patients with colon cancer.

Vivek Subbiah, MD, discusses the clinical implications of the approval of pralsetinib in patients with RET fusion–positive non–small cell lung cancer.

Debu Tripathy, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.

Christina L. Roland, MD, MS, FACS, discusses the results from a phase 2 study evaluating neoadjuvant checkpoint blockade study in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Courtney DiNardo, MD, MSCE, discusses the FDA approval of oral azacitidine (CC-486) in acute myeloid leukemia (AML).

Naval G. Daver, MD, discusses the tolerability of magrolimab plus azacitidine in patients with acute myeloid leukemia and myelodysplastic syndrome.

Srdan Verstovsek, MD, PhD, discusses the phase 2 MANIFEST study, which examined CPI-0610 as an “add-on” to ruxolitinib in patients with myelofibrosis.

Van K. Morris, MD, discusses the role of circulating tumor DNA in resected colon cancer.

Shubham Pant, MD, discusses targeting KRAS mutations in advanced or metastatic solid tumors.

Neeta Somaiah, MD, discusses ​remaining challenges in soft tissue sarcoma.

Eric Jonasch, MD, discusses the role of inhibiting hypoxia-inducible factor-2α in Von Hippel-Lindau disease–associated renal cell carcinoma.

Debu Tripathy, MD, discusses tucatinib and fam-trastuzumab deruxtecan-nxki as 2 exciting drug approvals in the constantly changing HER2-positive breast cancer treatment paradigm.

Sattva Neelapu, MD, discussed findings from the first-in-human phase 1 ALPHA study which demonstrated encouraging short-term efficacy, along with manageable toxicities, with ALLO-501 and ALLO-647.

Debu Tripathy, MD, discusses fam-trastuzumab deruxtecan-nxki versus ado-trastuzumab emtansine in HER2-expressing breast cancers.

Christina L. Roland, MD, MS, FACS, discusses the safety profile of neoadjuvant checkpoint blockade in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Michael Wang, MD, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma.

Shannon N. Westin, MD, MPH, discusses challenges with precision medicine in endometrial cancer. 

Michael Wang, MD, discusses the safety profile of ​the CAR T-cell therapy brexucabtagene autoleucel in ​relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, discusses the FDA approval of brexucabtagene autoleucel in mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the FDA approval of brexucabtagene autoleucel (Tecartus; formerly KTE-X19) in mantle cell lymphoma (MCL).

Shannon N. Westin, MD, MPH, discusses the rationale for administering the maintenance therapy in this setting and the broader potential of regimens combining PARP with other therapies.

Preetesh Jain, MD, PhD, discusses research efforts examining resistance patterns with venetoclax in mantle cell lymphoma.

Findings from an exploratory analysis of the phase 1/2 ZUMA-1 trial demonstrated clinical efficacy in patients with relapsed/refractory large B-cell lymphoma who were retreated with the CAR T-cell therapy axicabtagene ciloleucel.